Researchers led by Professor Oliver Brüstle at the University of Bonn have successfully converted immature blood cells from an 80-year-old donor directly into neural stem cells, reversing more than 60 years of molecular aging. Measurements using epigenetic clocks showed that the resulting brain-precursor cells registered as younger than 20 years old.
Gradual Rejuvenation and Human Safety Trials
Unlike traditional methods that rapidly reset cellular age by passing through an intermediate stem-cell stage, the University of Bonn technique skipped that phase. This allowed researchers to observe molecular rejuvenation gradually over more than 100 days. Professor Brüstle noted that tracking the process over 100 days enables scientists to analyze which substances accelerate or interrupt cellular age reversal, potentially offering insights into neurodegenerative conditions such as Alzheimer's disease.
Human clinical testing for cellular rejuvenation is already in its early stages. In January, U.S. regulators cleared Life Biosciences to test ER-100, an experimental therapy designed to rejuvenate damaged eye cells. On October 8, the company reported preliminary findings from a safety trial where three glaucoma patients tolerated ER-100 through 56 days, with two patients showing preliminary improvements in vision tests.
Capital Surges into Longevity Startups and Web3 Projects
Financial backing for life-extension research has accelerated rapidly across traditional venture capital and Web3 ecosystems. Longevity biotechnology attracted a record $18.4 billion in 2025, up from $4.7 billion in 2024. By mid-September 2026, the sector had brought in another $12.1 billion.
Key industry deployments include:
- NewLimit, co-founded by Coinbase co-founder Brian Armstrong, raised $435 million in June with Eli Lilly Ventures among its backers, aiming to start human testing for aged liver cell therapies in 2027 (as major platforms report their figures alongside crypto earnings season developments).
- Retro Biosciences, backed by Sam Altman, reached a $1.8 billion valuation in May and is testing an experimental Alzheimer's pill.
- Altos Labs has raised $3 billion to pursue cellular rejuvenation.
- VitaDAO, a decentralized crypto-funded organization, has backed more than 30 longevity projects.
Why It Matters
The transition from lab experiments to early human trials marks a critical shift for the longevity sector. While epigenetic clocks prove that cellular age can be reversed in laboratory dishes, commercial viability depends on safety and measurable efficacy in living patients. If initial safety trials like Life Biosciences' ER-100 lead to broader clinical success, institutional capital and decentralized governance ecosystems are poised to expand their funding for cellular rejuvenation technology.
